Matthew J. Matasar

8.3k total citations · 2 hit papers
190 papers, 3.9k citations indexed

About

Matthew J. Matasar is a scholar working on Pathology and Forensic Medicine, Oncology and Genetics. According to data from OpenAlex, Matthew J. Matasar has authored 190 papers receiving a total of 3.9k indexed citations (citations by other indexed papers that have themselves been cited), including 131 papers in Pathology and Forensic Medicine, 90 papers in Oncology and 56 papers in Genetics. Recurrent topics in Matthew J. Matasar's work include Lymphoma Diagnosis and Treatment (129 papers), Chronic Lymphocytic Leukemia Research (53 papers) and CAR-T cell therapy research (50 papers). Matthew J. Matasar is often cited by papers focused on Lymphoma Diagnosis and Treatment (129 papers), Chronic Lymphocytic Leukemia Research (53 papers) and CAR-T cell therapy research (50 papers). Matthew J. Matasar collaborates with scholars based in United States, Canada and Australia. Matthew J. Matasar's co-authors include Andrew D. Zelenetz, Craig H. Moskowitz, Sarit Assouline, Laurie H. Sehn, Alfred I. Neugut, Craig S. Sauter, Andrew McMillan, Elicia Penuel, Ariela Noy and Heiko Schöder and has published in prestigious journals such as Journal of Clinical Oncology, Blood and JNCI Journal of the National Cancer Institute.

In The Last Decade

Matthew J. Matasar

168 papers receiving 3.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

2019 459 citations Laurie H. Sehn, Alex F. Herrera et al. Journal of Clinical Oncology profile →
Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study

2022 244 citations Lihua E. Budde, Laurie H. Sehn et al. profile →

Peers

Matthew J. Matasar

PFM

ONCOL

GENET

NEURO

RNMI

Paul A. Hamlin United States

Chan Y. Cheah Australia

John Sweetenham United States

Catherine Sebban France

Christophe Fermé France

Francesco Merli Italy

Hervé Ghesquières France

Stefano Luminari Italy

Judith Trotman Australia

Lars Møller Pedersen Denmark

Paul A. Hamlin United States

Matthew J. Matasar

2.9k ×1.1

PFM

2.0k ×0.9

ONCOL

925 ×1.0

GENET

914 ×1.0

NEURO

431 ×0.8

RNMI

Citations per year, relative to Matthew J. Matasar Matthew J. Matasar (= 1×) peers Paul A. Hamlin

Countries citing papers authored by Matthew J. Matasar

Since Specialization

Citations

This map shows the geographic impact of Matthew J. Matasar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Matthew J. Matasar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Matthew J. Matasar more than expected).

Fields of papers citing papers by Matthew J. Matasar

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Matthew J. Matasar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Matthew J. Matasar. The network helps show where Matthew J. Matasar may publish in the future.

Co-authorship network of co-authors of Matthew J. Matasar

This figure shows the co-authorship network connecting the top 25 collaborators of Matthew J. Matasar. A scholar is included among the top collaborators of Matthew J. Matasar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Matthew J. Matasar. Matthew J. Matasar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ferrante, Jeanne M., Jenna Howard, Shawna V. Hudson, et al.. (2025). Perspectives of Lymphoma Survivors and Oncology Care Providers on Survivorship Care: A Qualitative Study. JCO Oncology Practice. 21(10). 1458–1467.

Caimi, Paolo F., et al.. (2024). Phase 1 Study of ARV-393, a PROTAC BCL6 Degrader, in Advanced Non-Hodgkin Lymphoma. Blood. 144(Supplement 1). 6505–6505. 4 indexed citations

Matasar, Matthew J., Marcus Messmer, Rashmi Khanal, et al.. (2024). Abstract CT245: Circulating tumor DNA and nivolumab maintenance: A pilot study in diffuse large B cell lymphoma. Cancer Research. 84(7_Supplement). CT245–CT245.

Smith, Alexandra N., Matthew J. Maurer, Julie Teruya‐Feldstein, et al.. (2024). Matched control analysis suggests that R-CHOP followed by (R)-ICE may improve outcome in non-GCB DLBCL compared with R-CHOP. Blood Advances. 8(9). 2172–2181. 2 indexed citations

Budde, Lihua E., Sarit Assouline, Laurie H. Sehn, et al.. (2024). Durable Responses With Mosunetuzumab in Relapsed/Refractory Indolent and Aggressive B-Cell Non-Hodgkin Lymphomas: Extended Follow-Up of a Phase I/II Study. Journal of Clinical Oncology. 42(19). 2250–2256. 34 indexed citations

Ghione, Paola, Erel Joffe, M. Lia Palomba, et al.. (2024). CD5 expression in marginal zone lymphoma does not predict inferior outcome and has similarities to indolent lymphomas. PubMed. 1(4). 100031–100031. 1 indexed citations

Lin, Shih‐Wen, et al.. (2024). Budget Impact of Introducing Fixed-Duration Mosunetuzumab for the Treatment of Relapsed or Refractory Follicular Lymphoma After Two or More Lines of Systemic Therapy in the USA. PharmacoEconomics. 42(5). 569–582. 1 indexed citations

Hamlin, Paul A., Anita Kumar, Matthew J. Matasar, et al.. (2024). A phase 1 trial of abexinostat with ibrutinib in relapsed/refractory mantle cell lymphoma and non-germinal center diffuse large B cell lymphoma. Leukemia & lymphoma. 65(14). 2224–2227.

Matasar, Matthew J., Nancy L. Bartlett, Mazyar Shadman, et al.. (2023). Mosunetuzumab Safety Profile in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma: Clinical Management Experience From a Pivotal Phase I/II Trial. Clinical Lymphoma Myeloma & Leukemia. 24(4). 240–253. 10 indexed citations

10.

Buege, Michael J., Esther Drill, Steven M. Horwitz, et al.. (2023). Low incidence of cardiotoxicity in patients with non‐Hodgkin lymphoma receiving EPOCH after prior anthracycline exposure. European Journal Of Haematology. 111(1). 96–102.

11.

Schuster, Stephen J., Ling‐Yuh Huw, Christopher R. Bolen, et al.. (2023). Loss of CD20 expression as a mechanism of resistance to mosunetuzumab in relapsed/refractory B-cell lymphomas. Blood. 143(9). 822–832. 34 indexed citations

12.

Salz, Talya, Emily C. Zabor, Peter de Nully Brown, et al.. (2022). Cardiovascular risk factors, radiation therapy, and myocardial infarction among lymphoma survivors. Acta Oncologica. 61(9). 1064–1068. 4 indexed citations

13.

Sehn, Laurie H., Mark Hertzberg, Stephen Opat, et al.. (2021). Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory DLBCL: survival update and new extension cohort data. Blood Advances. 6(2). 533–543. 107 indexed citations

14.

Budde, Elizabeth, Ajay K. Gopal, Won Seog Kim, et al.. (2021). A Phase 1 Dose Escalation Study of Igm-2323, a Novel Anti-CD20 x Anti-CD3 IgM T Cell Engager (TCE) in Patients with Advanced B-Cell Malignancies. Blood. 138(Supplement 1). 132–132. 22 indexed citations

15.

Joffe, Erel, Yan Leyfman, Esther Drill, et al.. (2021). Active surveillance of primary extranodal marginal zone lymphoma of bronchus-associated lymphoid tissue. Blood Advances. 5(2). 345–351. 7 indexed citations

16.

Matasar, Matthew J., et al.. (2021). Healthcare Resource Utilization and Costs of Patients with Relapsed/Refractory Follicular Lymphoma Receiving 3 or More Lines of Therapy. Blood. 138(Supplement 1). 1923–1923. 1 indexed citations

17.

Matasar, Matthew J., Chan Y. Cheah, Dok Hyun Yoon, et al.. (2020). Subcutaneous Mosunetuzumab in Relapsed or Refractory B-Cell Lymphoma: Promising Safety and Encouraging Efficacy in Dose Escalation Cohorts. Blood. 136(Supplement 1). 45–46. 27 indexed citations

18.

Borchmann, Sven, Erel Joffe, Craig H. Moskowitz, et al.. (2019). Active surveillance for nodular lymphocyte-predominant Hodgkin lymphoma. Blood. 133(20). 2121–2129. 26 indexed citations

19.

Kumar, Anita, Fushen Sha, Ahmed Toure, et al.. (2019). Patterns of survival in patients with recurrent mantle cell lymphoma in the modern era: progressive shortening in response duration and survival after each relapse. Blood Cancer Journal. 9(6). 50–50. 76 indexed citations

20.

Matasar, Matthew J., Myron S. Czuczman, Maria Alma Rodriguez, et al.. (2013). Ofatumumab in combination with ICE or DHAP chemotherapy in relapsed or refractory intermediate grade B-cell lymphoma. Blood. 122(4). 499–506. 45 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact